Erasca (ERAS) is trading higher after the company said it narrowed the timing for the anticipated Phase 1 monotherapy data readout for its pan-RAS molecular glue candidate, ERAS-0015. In an April 21, 2026 SEC filing, Erasca said it now expects data from the AURORAS-1 and JYP0015M101 trials no later than mid-May 2026, tightening its prior guidance of the first half of 2026.

For clinical-stage oncology names, timelines around first meaningful human efficacy and safety datasets are often key valuation drivers. By moving from a broad “first half” window to a more specific “no later than mid-May” timeline, the company effectively brings forward clarity for investors on whether ERAS-0015 is demonstrating early anti-tumor activity, tolerability, and other signals needed to justify expansion cohorts and subsequent development decisions.

ERAS-0015 is being evaluated in AURORAS-1, a Phase 1 trial in patients with RAS-mutant solid tumors, while Erasca’s licensor Guangzhou Joyo Pharmatech is running JYP0015M101 in China in patients with advanced solid tumors harboring specific RAS mutations. The next key watch item is the actual mid-May 2026 data disclosure—investors will be focused on response signals, duration, dose levels, safety profile, and whether the dataset supports combinations or accelerated development plans.